Plasmocin™ is an innovative product developed by InvivoGen that contains two antibiotics strongly active against mycoplasmas.
Benefits
Efficient - Plasmocin™ is active on both free mycoplasmas and intracellular forms. No drawback - No resistance in liquid cultures of mycoplasmas has ever been identified in repeated experiments. No apparent adverse effect on cellular metabolism is observed in all animal cell lines tested. Large spectrum - Also active at low concentrations on a broad range of Gram positive and Gram negative bacteria. Rapid - Plasmocin™ eliminates mycoplasma in as little as 2 weeks. Plasmocin™ can also be used as routine addition to the cell culture medium to prevent mycoplasma contamination.
• Plasmocin™ Treatment To eliminate mycoplasmas use Plasmocin™ (ant-mpt) at 25 μg/ml for two weeks in the infected culture. • Plasmocin™ Prophylactic To prevent mycoplasma contamination, use Plasmocin™ (ant-mpp) at 2.5 - 5 μg/ml on a regular basis in cell culture
Show All | Hide All
Description
Plasmocin™ is a well-established antimycoplasma reagent. It contains two bactericidal components strongly active against mycoplasmas that allow their elimination in only 2 weeks. The first component acts on the protein synthesis machinery while the second acts on the DNA replication. These two specific and separate targets are found only in mycoplasmas and many other bacteria and are completely absent in eukaryotic cells.
In contrast to other anti-mycoplasma compounds, Plasmocin™ is active on both free mycoplasmas and intracellular forms. This advantage is conferred by one component of Plasmocin™ which is actively transported into mammalian cells. It ensures that following treatment with Plasmocin™ a cell culture is not reinfected by mycoplasmas released from intracellular compartments of infected cells.
In all animal cell lines tested to date, even at five times the working concentration, no apparent adverse effect on cellular metabolism is observed.
No resistance in liquid cultures of mycoplasmas has ever been identified in repeated experiments attempting to measure the mutation rate. Therefore, development of resistant mycoplasma strains is virtually eliminated.
Plasmocin™ is also active at low concentrations on a broad range of Gram positive and Gram negative bacteria that are otherwise resistant to the mixture of streptomycin and penicillin, and exhibits no toxicity in eukaryotic cells.
Many cell lines infected by mycoplasmas have been successfully treated with Plasmocin™, including embryonic stem cells, hybridomas and retrovirus packaging cells.
Contents and Storage
Plasmocin™ is provided as a yellow solution either at a concentration of 25 mg/ml (Plasmocin™ Treatment) or 2.5 mg/ml (Plasmocin™ Prophylactic). One ml Plasmocin™ Treatment is enough to treat 1 L medium.
Plasmocin™ is shipped at room temperature. Store at -20°C.
Plasmocin™ Treatment (25mg/ml) is stable 1 week at 37°C, 1 month at 4°C, and 2 years when stored at –20°C. Plasmocin™ Prophylactic (2.5mg/ml) is stable 1 week at 37°C, 9 months at 4°C, and 2 years when stored at –20°C.
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations
and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
